Loading News...
Back to Dashboard

AbbVie Inc. (ABBV)

Real-time intraday values

Market Overview

From:
To:
ABBV Intraday
No data available
SymbolABBV
IPO DateJan 2, 2013
CEOMr. Robert A. Michael CPA
Full Time Employees57k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNYSE
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Performance
PeriodReturn %Value Change
1 Day
-1.09%
-2.35 US$
5 Days
-0.54%
-1.15 US$
1 Month
+7.37%
+14.64 US$
6 Months
-6.29%
-14.31 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of ABBV...

Key Statistics
Market Cap
376.95B
P/E Ratio
104.07
Div Yield
321.00%
52W High
$244.81
52W Low
$181.73

Analyst Consensus

CONSENSUSBuy
BULLISH2475.0%
NEUTRAL825.0%
BEARISH00.0%

52W Analyst Price Targets

Min Target
$184.00
Max Target
$328.00
Current$213.35
Avg Target$252.90

Analyst Recommendations

Precio Objetivo:$252.90($184.00 - $328.00)
FirmRatingTarget PriceUpside PotentialDate
Evercore ISI GroupOutperform$235.00+10.15%5/15/2026
Piper SandlerOverweight$298.00+39.68%5/14/2026
Evercore ISI GroupOutperform$236.00+10.62%5/4/2026
GuggenheimBuy$249.00+16.71%5/1/2026
Canaccord GenuityBuy$265.00+24.21%4/30/2026
Morgan StanleyOverweight$278.00+30.30%4/30/2026
Cantor FitzgeraldOverweight$240.00+12.49%4/30/2026
Piper SandlerOverweight$294.00+37.80%4/23/2026
Canaccord GenuityBuy$262.00+22.80%4/21/2026
GuggenheimBuy$249.00+16.71%4/10/2026
Community Thoughts

Share your analysis and sentiment on ABBV

Join the community to share your analysis